London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space

blonca9
Nov 21, 2024
1 min read

Updated: Nov 27, 2024

Robert Barrow discusses MindMed's LSD based program that is going into phase 3 studies for generalized anxiety disorder and major depressive disorder and an earlier stage R(-)-MDMA program for autism spectrum disorder.

Recent Posts

See All

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight